Expert review of neurotherapeutics
-
Expert Rev Neurother · Mar 2017
ReviewNeuroprogression and illness trajectories in bipolar disorder.
The longitudinal course of bipolar disorder is highly variable, and a subset of patients seems to present a progressive course associated with brain changes and functional impairment. Areas covered: We discuss the theory of neuroprogression in bipolar disorder. This concept considers the systemic stress response that occurs within mood episodes and late-stage deficits in functioning and cognition as well as neuroanatomic changes. ⋯ We found 315 abstracts and included 87 studies in our review. Expert commentary: We are of the opinion that the use of specific pharmacological strategies and functional remediation may be potentially useful in bipolar patients at late-stages. New analytic approaches using multimodal data hold the potential to help in identifying signatures of subgroups of patients who will develop a neuroprogressive course.
-
Epilepsy is significantly more frequent in AD patients than in age-matched controls, even though the true extent of the phenomenon is not clear yet. Areas covered: In this review, we describe in detail the available data on the pharmacological treatment of epilepsy in patients with AD. ⋯ The few data on the use of AEDs in AD patients suggest that newer AEDs (in particular lamotrigine and levetiracetam) might be good choices. Experimental data even support a potential role of some AEDs in modifying the disease course of AD.
-
Expert Rev Neurother · Feb 2017
Sufentanil sublingual formulation for the treatment of acute, moderate to severe postoperative pain in adult patients.
Sufentanil is a highly selective µ-opioid agonist commonly used by intravenous and intrathecal routes for acute pain. Sublingual sufentanil formulation for patient controlled analgesia (PCA) uses an innovative administration device that suspends a 15 µg nanotablet with a fixed lockout interval. The system is a non-invasive, less burdensome method of opioid delivery compared to intravenous and intrathecal routes. ⋯ Expert commentary: Under-treatment of acute pain is a substantial clinical problem. The initial experiences with the sublingual delivery system are encouraging. Sufentanil sublingual nanotablets intended for PCA device use are approved in Europe, and approval is pending in the United States.
-
Expert Rev Neurother · Dec 2016
ReviewPotential new complication in drug therapy development for amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron degeneration in the brain and spinal cord. Treatment development for ALS is complicated by complex underlying disease factors. Areas covered: Numerous tested drug compounds have shown no benefits in ALS patients, although effective in animal models. ⋯ Specific blood-CNS barrier damage in ALS patients, as a novel potential reason for the clinical failures in drug therapies, is discussed. Expert commentary: Pathological perivascular collagen IV accumulation, one unique characteristic of barrier damage in ALS patients, could be hindering transport of therapeutics to the CNS. Restoration of B-CNS-B integrity would foster delivery of therapeutics to the CNS.
-
Expert Rev Neurother · Nov 2016
ReviewAnesthesia and cognitive disorders: a systematic review of the clinical evidence.
Preclinical and clinical evidence suggest an association between anesthesia and cognitive disorders ranging from postoperative chronic dysfunction to Alzheimer's disease. Recent clinical insights are summarized in this paper. ⋯ Expert commentary: There is a growing interest in establishing the possible relationship between anesthesia and the onset and progression of cognitive disorders. Further studies are required to determine the methods of monitoring anesthesia in older adults with dementia undergoing surgical procedures.